In-hospital costs of coronary stent implantation with and without eptifibatide (The ESPRIT trial)

Among patients who underwent coronary stenting and were randomized to eptifibatide (n = 1,040) or placebo (n = 1,024), use of eptifibatide reduced initial procedural costs by $151/patient ($4,423 vs $4,574, p = 0.005) and costs related to ischemic complications by $61/patient ($283 vs $344, p = 0.002). When the cost of study drug was included, total initial hospital costs were increased by <$300/patient with eptifibatide compared with placebo ($10,632 vs $10,395, p <0.001).